Form 8-K Mirum Pharmaceuticals, For: Jun 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Form 8-K Mirum Pharmaceuticals, For: Jun 17
June 17, 2024 3:22 PM EDT
Evercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $62.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "MIRM is one of the rare, profitable smallcaps in our coverage based on their base business alone (which... More
June 17, 2024 3:00 PM EDT
Citi analyst David Lebowitz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $64.00 (from $38.00) while maintaining a Buy rating.
The analyst comments "In todays call, Mirum highlighted that volixibat performance in both PSC & PBC beat expectations. Early best-in-disease itch... More
June 17, 2024 1:37 PM EDT
Morgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $57.00 (from $53.00) while maintaining a Overweight rating.
The analyst comments "Interim Ph2b volixibat results better than expected, as robust activity observed in PBC and blinded analysis in... More
June 17, 2024 10:28 AM EDT
Stifel analyst Dae Gon Ha reiterated a Buy rating and $48.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today's interim analyses for volixibat studies - primary biliary cholangitis (PBC; VANTAGE) and primary sclerosing cholangitis (PSC; VISTAS) - offer promising... More
June 17, 2024 8:41 AM EDT
Citi analyst David Lebowitz reiterated a Buy rating and $38.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "This morning, Mirum shared positive interim updates from volixibats Ph2b VISTAS and VANTAGE trials in primary sclerosing cholangitis (PSC) and primary biliary cholangitis... More
